CCTG has opened the anticipated international brain cancer study CCTG CE9 (LUMOS2) - joining forces with the Australian Cooperative Trials Group for Neuro-Oncology (COGNO) to make enrollment accessible to Canadian patients.
Venetoclax and HMA-based Therapies for the Treatment of Older and Unfit Adults with Newly Diagnosed FLT3-mutated AML: A myeloMATCH Treatment Trial
VIGOR: Vorasidenib as Maintenance Treatment after First-line Chemoradiotherapy in IDH-mutant Grade 2 or 3 Astrocytoma
Botensilimab + Balstilimab vs Best Supportive Care as Therapy in Chemo-refractory, Unresectable, Colorectal Adenocarcinoma: The BATTMAN Trial
Role of Antibiotic Therapy or Immunoglobulin On iNfections in hAematoLogy Platform Trial - RATIONAL-PT
The CCTG ES3 NEEDS international esophageal cancer clinical trial is now opened in Canada. The study is investigating whether delaying surgery for patients with squamous cell carcinoma of the esophagus is as good as the current treatment.
Phase 2 Trial of ASTX727 and Venetoclax Compared with ASTX727, Venetoclax, and Enasidenib for Newly Diagnosed Older Adults with IDH2 Mutant AML - A myeloMATCH Substudy
Eradicating MRD in Patients with AML prior to Stem Cell Transplant (ERASE)
LUNA-2: LND101 in Unresectable Non-Small Cell Lung Cancer: A Randomized Phase II Trial
RAINBO-ORANGE: Treatment of Endometrial Cancer Based On Molecular Features
Delayed Reduced Volume and Dose Elective Radiotherapy (REVERT) in Patients with HNSCC
Autologous Stem Cell Transplant in Peripheral T Cell Lymphoma that Achieved a First Complete Remission (CR1) Following Induction Therapy (PTCL-STAT)
CCTG is pleased to announce the agenda for the Plenary Session at the #CCTG2026 Spring Meeting.
Dr. Rebecca Auer is our guest speaker this year at the Maria Ricci Memorial Lectureship In Oncology taking place at the CCTG Spring Meeting
CCTG is delighted to celebrate the distinguished career and dedication of Dr Glenwood Goss, who's work was recognized at the 2026 Annual Spring Meeting of Participants last weekend in Toronto. Dr Goss was awarded the Dr. Joseph Pater Founder’s Award for Excellence in Clinical Trials Research presented to a clinical trials research investigator whose leadership and body of work has contributed to significant advances in the understanding, diagnosis, treatment, cure, and prevention of cancer.
The Team Awards for Phase III CCTG trials is presented to trial teams from member centres for performance in trial accrual, local activation timelines, compliance metrics and team performance is determined by the Executive IND Committee and Clinical Trials Committee.
We are pleased to inform you that the Canadian Cancer Trials Group (CCTG) is organizing our next Clinical Research Associate (CRA) Lunch and Learn training program, to be held on Wednesday, May 13th, 2026, at 12 pm ET on the topic: NCTN Clinical Trial Support Unit (CTSU) OPEN System and upcoming changes
Congratulations to Lynn Dwernychuk for being honoured with the CCTG Award for Excellence in Clinical Trials Conduct, presented to her last weekend at the Annual Spring Meeting of Participants. Lynn was recognized by her peers as an individual who exemplifies excellence in clinical trial operations and compliance. She serves as the Director of Clinical Research at the Saskatchewan Cancer Agency and holds an Adjunct Professorship with the College of Graduate Studies and Research at the University of Saskatchewan.
CCTG is delighted to recognize the early career of Dr. Jelena Lukovic who was presented with the CCTG Dr. Ralph Meyer Phase III Young Investigator Award this past weekend at the Spring Meeting of Participants in Toronto. This award is given to an outstanding young investigator who is working on a CCTG Phase III clinical trial.She is the Canadian PI for the international NEEDS trial evaluating definitive chemoradiotherapy for squamous cell esophageal cancer.
CCTG is pleased to recognize the BC Cancer–Kelowna IND240 Clinical Trials Team with the IND Team Award which was presented to the recipients this weekend at the CCTG Spring Meeting. The award is presented to Non-MD trial team members from member centres for their efforts and dedication to the success of clinical trials in the IND Program.
